

February 09, 2010  
Mumbai

## CRISIL Research assigns IPO grade 4/5 to Glenmark Generics Ltd.

CRISIL has assigned a CRISIL IPO Grade "4/5" (pronounced "four on five") to the proposed initial public offer (IPO) of Glenmark Generics Ltd (GGL). This grade indicates that the fundamentals of the IPO are above average relative to the other listed equity securities in India. However, this grade is not an opinion on whether the issue price is appropriate in relation to the issue fundamentals. The grade is not a recommendation to buy / sell or hold the graded instrument, or a comment on the graded instrument's future market price or its suitability for a particular investor.

The IPO grade reflects the company's status as a fast growing Indian generics company. According to estimates by CRISIL Research, drugs worth an estimated USD 137 billion is scheduled to go off-patent in the US and Europe over the next 5 years, which implies significant generics opportunity for India. GGL, given its dominant position among Indian players in the global generics market, is well placed to capitalise on the emerging opportunities in generics and to consolidate its presence in the regulated markets of US and Europe. The grading takes into account the company's strong product pipeline and strategy of focusing on niche and complex molecules in the US market. The grading also takes into account the relevant experience and domain expertise of the promoter and the top management and their demonstrated capabilities in driving business growth.

The grading is, however, constrained by the stiff competition the company faces from the Indian as well as the international generic players operating in the US and European markets. Further, the grading is also affected by the fact that the company's revenues and profitability in the pharmaceutical industry will remain sensitive to the extent of competition (through the entire R & D process till the time of FDA approval). The grading is tempered by the risk associated with non-compliance of the regulatory requirements or cGMP norms and their impact on business growth.

The company's revenues amounted to Rs 10.4 billion in 2008-09, of which its US formulation business accounted for 71 per cent. During the year, the company's operating margins were at 30.4 per cent, which were relatively higher than that of its peers. The higher profitability can be attributed to the company's strategy of focusing on niche segments where the realisations are better due to relatively lower competition levels.

### About the company and the issue

GGL, a subsidiary of Glenmark Pharmaceuticals Limited (GPL), is an integrated generics and API (Active pharmaceutical ingredient) player. GGL has a business presence in North America, EU and South America (Argentina) besides maintaining marketing front-ends. GGL markets APIs to more than 65 countries across the world. The manufacturing facilities of the company are situated in Goa, Ankleshwar (Gujarat), Kurkumbh and Mohol (Maharashtra) in India. The company's API plant at Ankleshwar and its formulation plant at Goa are approved by the FDA, USA and MHRA, UK.

GGL's management is headed by Mr. Glenn Saldanha, Chairman and Non-Executive director of the company who has over 14 years of relevant experience. Mr. Terrance Coughlin and Mr. Jalaj Sharma are the two whole time directors and Mr. R. V. Desai is the non-executive director. These four top management personnel are in charge of strategic business planning for the company. GGL has four independent directors - Mr. Julio F. Ribeiro, Mr. Sridhar Gorthi, Mr. D. R. Mehta and Mr. Natvarlal Bhimbhai Desai.

Of the expected issue size of Rs 5,750 million, GGL plans to utilise around Rs 4,800 million to part pay the loan due to GHSA (Glenmark Holding S.A., subsidiary of parent company - GPL) for the purchase of its generics business. The rest is expected to be used for general corporate purposes.

### About CRISIL IPO Grading

CRISIL IPO (Initial Public Offering) Grading is an opinion on the fundamentals of the graded issue that reflects CRISIL's independence and expertise. This opinion is expressed as a relative assessment in relation to other listed equity securities in India. The assessment is based on a grading exercise carried out by industry specialists from CRISIL Research. A CRISIL IPO Grade 5/5 indicates strong fundamentals and a CRISIL IPO Grade 1/5 indicates poor fundamentals. CRISIL IPO Grading reflects its assessment of the graded company's equity fundamentals as distinct from an assessment of debt fundamentals. A CRISIL IPO Grade should not be construed to mean a comment on the price of the graded security nor is it a recommendation to invest or not to invest in the graded security.

Media Contact	Analytical Contact
<b>Mitu Samar</b> <b>Head, Market Development &amp; Communications</b> <b>CRISIL Limited</b> Tel: +91-22- 3342 1838 Mobile: +91- 98200 61934 Fax: +91-22- 3342 3001 E-mail: <a href="mailto:msamar@crisil.com">msamar@crisil.com</a>	<b>Chetan Majithia</b> <b>Head, CRISIL Equities</b> Tel: +91-22- 3342 4148 E-mail: <a href="mailto:chetanmajithia@crisil.com">chetanmajithia@crisil.com</a>

### About CRISIL Limited

CRISIL is India's leading Ratings, Research, Risk and Policy Advisory Company.

### About CRISIL Research

CRISIL Research is India's largest independent, integrated research house. We leverage our unique, integrated research platform and capabilities spanning the entire economy-industry company spectrum to deliver superior perspectives and insights to over 600 domestic and global clients, through a range of subscription products and customised solutions.

#### CRISIL PRIVACY NOTICE

Contacting us via e-mail or registering with CRISIL reveals your e-mail address and any other information you include such as phone number and/or mailing address. We will use this information to help us process your registration, fulfill your request or respond to your inquiry. All of your personal information will be stored in a secure database in India. Access to this database is limited to authorized persons.

Occasionally, we use data collected about customers and prospects to inform them about products or services from CRISIL, and our parent company Standard & Poor's (a subsidiary of The McGraw-Hill Companies), and reputable outside companies that may be of interest to them. Many of our customers find these e-mail promotions valuable, whether they are shopping for merchandise, taking advantage of a special offer, or purchasing unique services. On rare occasions, and subject to applicable laws, CRISIL may also share your information with outside "3rd Party" vendors who will be authorized to use this information solely to perform services (such as a "mailing" house) on our behalf.

If at any time you would like your name removed from lists that are shared for promotional reasons within CRISIL, Standard & Poor's, and with other units of The McGraw-Hill Companies, or with third parties simply send a written request to [privacy@crisil.com](mailto:privacy@crisil.com) or Privacy Official, CRISIL House, Central Avenue, Hiranandani Business Park, Powai, Mumbai - 400 076, India.

You can also send an email request to [privacy@crisil.com](mailto:privacy@crisil.com) if you would like to confirm the accuracy of the information we have collected from you, or if you have questions about the uses of this information.

For more information about The McGraw-Hill Companies Privacy Policy, please visit [www.mcgrawhill.com/privacy.html](http://www.mcgrawhill.com/privacy.html)

Last updated: 01 January, 2010

#### Disclaimer

A CRISIL IPO Grading is a one-time assessment and reflects CRISIL's current opinion on the fundamentals of the graded equity issue in relation to other listed equity securities in India. A CRISIL IPO Grading is neither an audit of the issuer by CRISIL nor is it a credit rating. Every CRISIL IPO Grading is based on the information provided by the issuer or obtained by CRISIL from sources it considers reliable. CRISIL does not guarantee the completeness or accuracy of the information on which the grading is based. A CRISIL IPO Grading is not a recommendation to buy / sell or hold the graded instrument; it does not comment on the issue price, future market price or suitability for a particular investor.

CRISIL is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of CRISIL IPO Gradings. For information on any IPO grading assigned by CRISIL, please contact 'Client Servicing' at +91-22-33423561, or via e-mail: [clientservicing@crisil.com](mailto:clientservicing@crisil.com).

For more information on CRISIL IPO Gradings, please visit <http://www.crisil.com/ipo-gradings>

This press release is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The Press release may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution of its Press Releases for consideration or otherwise through any media including websites, portals etc.